In a vote on draft plans to update an EU law on veterinary medicines, they advocate banning collective and preventive antibiotic treatment of animals, and back measures to stimulate research into new medicines.

"Today’s vote is a big step forward for animal health and the fight against antibiotic resistance. With these new rules, we can better circumscribe and control the use of antibiotics in farm animals and thus reduce the risk that potential resistances will emerge.

"The text will also help to improve the availability of medicines and drive innovation forward, so as to expand the therapeutic arsenal available to vets. I welcome the broad consensus on this report, which should promote public health and consumer protection," said lead MEP Françoise Grossetête (EPP, FR).

Her report was approved by 60 votes to 2.

Veterinary medicines must not under any circumstances serve to improve performance or compensate for poor animal husbandry, say MEPs, who advocate limiting the prophylactic use of antimicrobials (i.e. as a preventive measure, in the absence of clinical signs of infection) to single animals and only when fully justified by a veterinarian.

Metaphylactic use (i.e. treating a group of animals when one shows signs of infection) must be restricted to clinically-ill animals and to single animals that are identified as being at a high risk of contamination, in order to prevent bacteria from spreading further in the group, they say.

MEPs urge farm animal owners and keepers to use stocks with suitable genetic diversity, in densities that do not increase the risk of disease transmission, and to isolate sick animals from the rest of the group.

Other measures:

• To help tackle antimicrobial resistance, the revised law would empower the European Commission to designate antimicrobials which are to be reserved for human treatment.
• To encourage research into new antimicrobials, MEPs advocate incentives, including longer periods of protection for technical documentation on new medicines, commercial protection of innovative active substances, and protection for significant investments in data generated to improve an existing antimicrobial product or to keep it on the market.
• In a separate vote, the committee approved a report amending another law to reflect the fact that centralised marketing authorisation for veterinary medicinal products is being decoupled from that for medicines for humans.

Both reports will be debated and put to a vote during the March/April plenary sessions in Strasbourg.